Seek Returns

PCVX vs. RPRX: Vaxcyte vs. Royalty Pharma Stock Comparison

How do Vaxcyte (PCVX) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Vaxcyte (PCVX) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but PCVX is classified in Biotechnology while RPRX is classified in Pharmaceuticals.

Company profile comparison for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
Profile ItemPCVXRPRX
NameVaxcyte Inc.Royalty Pharma plc Class A Ordinary Shares
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization10.11 billion USD38.70 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateJune 12, 2020June 16, 2020
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

PCVX
RPRX
GSPC
Loading price history…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Vaxcyte (PCVX) and Royalty Pharma (RPRX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Vaxcyte (PCVX) and Royalty Pharma (RPRX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
Total Return (1Y)59.00%81.08%
Total Return (3Y, Annualized)11.29%39.21%
Total Return (5Y, Annualized)21.60%14.22%

Risk Profile

Drawdown History

PCVX
RPRX
GSPC
Loading price history…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Vaxcyte (PCVX) and Royalty Pharma (RPRX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
Volatility (1Y, Annualized)56.01%22.05%
Beta (5Y)1.260.36
Max Drawdown (5Y)-76.22%-41.98%
Avg. Volume (3M)2.12M3.10M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
PCVX and RPRX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
Sharpe Ratio (1Y)0.983.48
Sortino Ratio (1Y)1.765.72

Profitability

ROE (TTM)

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Royalty Pharma (RPRX) reports 12.09%, ranking against industry peers normally.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-42.68%

Max
109.18%
Q3
6.23%
Median
-26.66%
PCVX
-42.68%
Q1
-64.05%
Min
-167.77%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.09%

Max
109.18%
RPRX
12.09%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Royalty Pharma (RPRX) at 25.70% converts revenue to bottom-line profit above its industry’s benchmark range, while Vaxcyte (PCVX) at 0.00% keeps roughly the typical share for its industry.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
PCVX
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.70%

RPRX
25.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
83.12%
Q3
14.77%
PCVX
0.00%
Median
0.00%
Q1
-78.82%
Min
-207.40%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.32%

Max
83.12%
RPRX
81.32%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
ROE (TTM)-42.68%12.09%
ROA (TTM)-24.98%5.43%
Net Margin (TTM)0.00%25.70%
Operating Margin (TTM)0.00%81.32%
Gross Margin (TTM)0.00%99.79%

Growth

Revenue Growth

Only one side can be read here: Royalty Pharma (RPRX) reports revenue growth of 5.06%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Royalty Pharma (RPRX) reports EPS growth of 23.09%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
Revenue Growth (YoY)--5.06%
Revenue Growth (3Y CAGR)--2.06%
EPS Growth (YoY)--23.09%
EPS Growth (3Y CAGR)--161.10%

Financial Strength

Current Ratio (MRQ)

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while Royalty Pharma (RPRX) at 1.29 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RPRX.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.56

Max
25.13
Q3
12.13
Median
5.52
PCVX
4.56
Q1
2.47
Min
0.10

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RPRX
1.29
Min
0.10
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Vaxcyte (PCVX) at 0.09 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
PCVX
0.09
Q1
0.02
Min
0.00

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max
1.42
RPRX
0.88
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
Current Ratio (MRQ)4.561.29
Debt / Equity (MRQ)0.090.88
Net Debt / EBITDA--4.76

Dividends

Dividend Yield (TTM)

Vaxcyte (PCVX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37%

RPRX
1.37%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Vaxcyte (PCVX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

PCVX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.46%

RPRX
60.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
Dividend Yield (TTM)0.00%1.37%
Dividend Payout Ratio (TTM)0.00%60.46%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Royalty Pharma (RPRX) trades at 43.99 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
PCVX
--

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.99

Max
85.34
RPRX
43.99
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): PCVX does not report P/E ratio, so it has no value marker; RPRX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for Royalty Pharma (RPRX), whose P/S ratio of 14.79 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
PCVX
--

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.79

Max
58.18
Q3
25.77
RPRX
14.79
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): PCVX does not report P/S ratio, so it has no value marker; RPRX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

On P/B ratio, both Vaxcyte (PCVX) at 3.83 and Royalty Pharma (RPRX) at 4.39 are valued close to their industries’ norm against book — neither stands out from peers.

PCVX

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.83

Max
13.53
Q3
6.54
PCVX
3.83
Median
3.25
Q1
1.69
Min
-5.59

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.39

Max
13.53
Q3
6.54
RPRX
4.39
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Vaxcyte (PCVX) vs. Royalty Pharma (RPRX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Vaxcyte (PCVX) and Royalty Pharma (RPRX)
MetricPCVXRPRX
P/E Ratio (TTM)--43.99
P/S Ratio (TTM)--14.79
P/B Ratio (MRQ)3.834.39
Free Cash Flow Yield (TTM)-5.24%-1.16%